Effect and Safety of Rosuvastatin in Acute Ischemic Stroke
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background and Purpose The benefit of statins in acute stroke remains uncertain. Statins may prevent stroke recurrence during the acute stage of stroke via pleiotropic effects. However, statins may increase the risk of intracerebral hemorrhage. We investigated the effect and safety of rosuvastatin in acute stroke patients. Methods This randomized, double-blind, multi-center trial compared rosuvastatin 20 mg and placebo in statin-naïve stroke patients who underwent diffusion-weighted imaging (DWI) within 48 hours after symptom onset. The primary outcome was occurrence of new ischemic lesions on DWI at 5 or 14 days. Results This trial was stopped early after randomization of 316 patients due to slow enrollment. Among 289 patients with at least one follow-up imaging, the frequency of new ischemic lesions on DWI was not different between groups (rosuvastatin: 27/137, 19.7% vs. placebo: 36/152, 23.6%) (relative risk 0.83, 95% confidence interval 0.53–1.30). Infarct volume growth at 5 days (log-transformed volume change, rosuvastatin: 0.2±1.0 mm3 vs. placebo: 0.3±1.3 mm3; P=0.784) was not different, either. However, hemorrhagic infarction or parenchymal/subarachnoid hemorrhage on gradient-recalled echo magnetic resonance imaging occurred less frequently in the rosuvastatin group (6/137, 4.4%) than the placebo group (22/152, 14.5%, P=0.007). Among 314 patients with at least one dose of study medication, progression or clinical recurrence of stroke tended to occur less frequently in the rosuvastatin group (1/155, 0.6% vs. 7/159, 4.4%, P=0.067). Adverse events did not differ between groups. Conclusions The efficacy of rosuvastatin in reducing recurrence in acute stroke was inconclusive. However, statin use was safe and reduced hemorrhagic transformation.
Abstract
Background and Purpose The benefit of statins in acute stroke remains uncertain. Statins may prevent stroke recurrence during the acute stage of stroke via pleiotropic effects. However, statins may increase the risk of intracerebral hemorrhage. We investigated the effect and safety of rosuvastatin in acute stroke patients. Methods This randomized, double-blind, multi-center trial compared rosuvastatin 20 mg and placebo in statin-naïve stroke patients who underwent diffusion-weighted imaging (DWI) within 48 hours after symptom onset. The primary outcome was occurrence of new ischemic lesions on DWI at 5 or 14 days. Results This trial was stopped early after randomization of 316 patients due to slow enrollment. Among 289 patients with at least one follow-up imaging, the frequency of new ischemic lesions on DWI was not different between groups (rosuvastatin: 27/137, 19.7% vs. placebo: 36/152, 23.6%) (relative risk 0.83, 95% confidence interval 0.53–1.30). Infarct volume growth at 5 days (log-transformed volume change, rosuvastatin: 0.2±1.0 mm3 vs. placebo: 0.3±1.3 mm3; P=0.784) was not different, either. However, hemorrhagic infarction or parenchymal/subarachnoid hemorrhage on gradient-recalled echo magnetic resonance imaging occurred less frequently in the rosuvastatin group (6/137, 4.4%) than the placebo group (22/152, 14.5%, P=0.007). Among 314 patients with at least one dose of study medication, progression or clinical recurrence of stroke tended to occur less frequently in the rosuvastatin group (1/155, 0.6% vs. 7/159, 4.4%, P=0.067). Adverse events did not differ between groups. Conclusions The efficacy of rosuvastatin in reducing recurrence in acute stroke was inconclusive. However, statin use was safe and reduced hemorrhagic transformation.
참고문헌 (30)
- Baigent C, "Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins", Lancet, 366, pp.1267~1278 (2005)
- Amarenco P, "High-dose atorvastatin after stroke or transient ischemic attack", N Engl J Med, 355, pp.549~559 (2006)
- Tziomalos K, "Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke", Atherosclerosis, 243, pp.65~70 (2015)
- Bourcier T, "HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells", Arterioscler Thromb Vasc Biol, 20, pp.556~562 (2000)
- Schäfer A, "Rosuvastatin reduces platelet activation in heart failure : role of NO bioavailability", Arterioscler Thromb Vasc Biol, 25, pp.1071~1077 (2005)
- Sukhova GK, "Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol", Arterioscler Thromb Vasc Biol, 22, pp.1452~1458 (2002)
- Ní Chróinín D, "Statin therapy and outcome after ischemic stroke : systematic review and meta-analysis of observational studies and randomized trials", Stroke, 44, pp.448~456 (2013)
- Biffi A, "Statin treatment and functional outcome after ischemic stroke : case-control and meta-analysis", Stroke, 42, pp.1314~1319 (2011)
- Keun-Sik Hong, "Statins in Acute Ischemic Stroke: A Systematic Review", 대한뇌졸중학회지, 17(3), pp.282~301 (2015), 대한뇌졸중학회
- Collins R, "Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions", Lancet, 363, pp.757~767 (2004)
- Squizzato A, "Statins for acute ischemic stroke", Cochrane Database Syst Rev, 8, pp.CD007551~ (2011)
- Jauch EC, "Guidelines for the early management of patients with acute ischemic stroke : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2013, pp.44, 870~947
- Kang DW, "Early ischemic lesion recurrence within a week after acute ischemic stroke", Ann Neurol, 54, pp.66~74 (2003)
- Kang DW, "Early recurrent ischemic lesions on diffusion-weighted imaging in symptomatic intracranial atherosclerosis", Arch Neurol, 64, pp.50~54 (2007)
- Chimowitz MI, "Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis", N Engl J Med, 352, pp.1305~1316 (2005)
- Ferguson GG, "The North American Symptomatic Carotid Endarterectomy Trial : surgical results in 1415 patients", Stroke, 30, pp.1751~1758 (1999)
- Hacke W, "Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)", JAMA, 274, pp.1017~1025 (1995)
- Nam HS, "Prediction of long-term outcome by percent improvement after the first day of thrombolytic treatment in stroke patients", J Neurol Sci, 281, pp.69~73 (2009)
- Philip B. Gorelick, "Primary and Comprehensive Stroke Centers:History, Value and Certification Criteria", 대한뇌졸중학회지, 15(2), pp.78~89 (2013), 대한뇌졸중학회[DOI]
- Kennedy J, "Fast assessment of stroke and transient ischaemic attack to prevent early recurrence(FASTER) : a randomised controlled pilot trial", Lancet Neurol, 6, pp.961~969 (2007)
- Beer C, "A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan", Int J Stroke, 7, pp.104~111 (2012)
- Montaner J, "Simvastatin in the acute phase of ischemic stroke : a safety and efficacy pilot trial", Eur J Neurol, 15, pp.82~90 (2008)
- Iadecola C, "The immunology of stroke : from mechanisms to translation", Nat Med, 17, pp.796~808 (2011)
- Aikawa M, "Dietary lipid lowering reduces tissue factor expression in rabbit atheroma", Circulation, 100, pp.1215~1222 (1999)
- Hackam DG, "Statins and intracerebral hemorrhage : a retrospective cohort study", Arch Neurol, 69, pp.39~45 (2012)
- McKinney JS, "Statin therapy and the risk of intracerebral hemorrhage : a meta-analysis of 31 randomized controlled trials", Stroke, 43, pp.2149~2156 (2012)
- Everett BM, "Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels(<30 mg", dl)with rosuvastatin 20 mg daily(from JUPITER), 2014, pp.114, 1682~1689
- Heo JH, "Matrix metalloproteinases increase very early during experimental focal cerebral ischemia", J Cereb Blood Flow Metab, 19, pp.624~633 (1999)
- Sapienza P, "Dose-dependent effect of rosuvastatin in the regulation of metalloproteinase expression", Ann Vasc Surg, 25, pp.823~829 (2011)
- Wang S, "Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes", Stroke, 37, pp.1910~1912 (2006)